Cesare Cozzarini
Vita-Salute San Raffaele University
Internal medicineRadiologyUrologySurgeryOncologyProstateTomotherapyAdjuvantProstatectomyProstate cancerLymph nodeToxicityNuclear medicineIn patientAdjuvant radiotherapyPost prostatectomySalvage radiationRadiation therapyMedicineUrinary system
398Publications
43H-index
5,080Citations
Publications 396
Newest
#1Alberto Martini (UniSR: Vita-Salute San Raffaele University)H-Index: 28
#2Nicola Fossati (UniSR: Vita-Salute San Raffaele University)H-Index: 36
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 96
view all 25 authors...
Abstract Intermediate clinical endpoints (ICEs) might aid in trial design and potentially expedite study results. However, little is known about the most informative ICE for patients receiving salvage radiation therapy (sRT) after radical prostatectomy. To investigate the most informative ICE for patients receiving sRT, we used a multi-institutional database encompassing patients treated at eight tertiary centers. Overall, 1301 men with node-negative disease who had not received any form of andr...
Source
Abstract Purpose To implement knowledge-based (KB) automatic planning for helical TomoTherapy (HTT). The focus of the first clinical implementation was the case of high-risk prostate cancer, including pelvic node irradiation. Methods and Materials One hundred two HTT clinical plans were selected to train a KB model using the RapidPlan tool incorporated in the Eclipse system (v13.6, Varian Inc). The individually optimized KB-based templates were converted into HTT-like templates and sent automati...
Source
#1Andrea BresolinH-Index: 1
#2Adriana FaiellaH-Index: 5
Last. Cesare CozzariniH-Index: 43
view all 24 authors...
Abstract Background and purpose To assess bowel dose-volume relationships for acute patient-reported intestinal symptoms of patients treated with whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer. Materials and methods Complete data of 415 patients enrolled in a multi institute, prospective trial (#NCT02803086) treated with radical (31%), adjuvant (33%) and salvage (36%) intent at a median dose to pelvic nodes/lymph-nodal area of 53Gy were available. The most severe change...
Source
#1N. Di MuzioH-Index: 11
Last. Andrei FodorH-Index: 13
view all 15 authors...
Source
#2Andrea BresolinH-Index: 1
Last. Cesare CozzariniH-Index: 43
view all 20 authors...
Source
#1Andrea BresolinH-Index: 1
Last. Cesare CozzariniH-Index: 43
view all 20 authors...
Source
#2Andrea BresolinH-Index: 1
Last. Cesare CozzariniH-Index: 43
view all 7 authors...
Source
#1Fernando MunozH-Index: 18
#2Giuseppe SanguinetiH-Index: 37
Last. Cesare CozzariniH-Index: 43
view all 20 authors...
Source
#1Marco CatucciH-Index: 1
#2Veronica BassoH-Index: 15
Last. Anna MondinoH-Index: 29
view all 12 authors...
Background Adoptive T cell therapy (ACT) has become a promising option for cancer patients. While tumor-infiltrating lymphocytes were initially exploited as a source of tumor reactive lymphocytes, T cells genetically redirected to the tumor by TCR/CAR gene transfer are now in clinical validation. In the case of solid tumors, unfavorable immunosuppressive microenvironments remain recognized barriers to therapeutic efficacy. We have recently reported that the therapeutic activity of ACT against po...
Source
#1Roberta CastriconiH-Index: 6
#2C. FiorinoH-Index: 7
Last. Riccardo CalandrinoH-Index: 32
view all 7 authors...
Source